This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia, 2004; 18: 1711–1716.
Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89–94.
Arcaini L, Paulli M, Boveri E, Vallisa D, Bernuzzi P, Orlandi E et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107–115.
Pitini V, Arrigo C, Righi M, Scaffidi M, Sturniolo G . Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma. Br J Haematol 2004; 124: 252–253.
Levine AM, Shimodara S, Lai MMC . Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon alpha. N Engl J Med 2004; 349: 2078–2079.
Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950–1956.
Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97: 1555–1559.
Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77: 2604–2613.
Evans AS, Mueller NE . Viruses and cancer: causal associations. Ann Epidemiol 1990; 1: 71–92.
Luppi M, Negrini R . MALT lymphomas: epidemiology and infectious agents. In: Zucca E, Bertoni F (eds). MALT Lymphomas, 2002. Eurekah.com. Georgetown, TX, USA: Landes/Eurekah.
Rabkin CS, Tess BH, Christianson RE, Wright WE, Waters DJ, Alter HJ et al. Prospective study of hepatitis C viral infection as risk factor for subsequent B cell neoplasia. Blood 2002; 99: 4240–4242.
Mele A, Pulsoni A, Bianco E, Musto P, Szkio A, Sanpaolo MG et al. Hepatitis C virus and B-cell non Hodgkin lymphomas: an Italian multicenter case–control study. Blood 2003; 102: 996–999.
Ohsawa M, Tomita Y, Hashimoto M, Kanno H, Aozasa K . Hepatitis C viral genome in a subset of primary hepatic lymphomas. Mod Pathol 1998; 11: 471–478.
Swaminathan S . Molecular biology of Epstein–Barr virus and Kaposi's sarcoma-associated herpesvirus. Sem Hematol 2003; 40: 107–115.
Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S . The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745–3749.
Hermouet S, Corre I, Gassin M, Bigot-Corbel E, Sutton CA, Casey JW . Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukaemia. N Engl J Med 2003; 348: 178–179.
Weissman IL, McGrath MS . Retrovirus lymphomagenesis: relationship of normal immune receptors to malignant cell proliferation. Curr Top Microbiol Immunol 1982; 98: 103–112.
Mann DL, DeSantis P, Mark G, Pfeifer A, Newman M, Gibbs N et al. HTLV-I-associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science 1987; 236: 1103–1106.
Machida K, Cheng KT-N, Sung VM-H, Shimodaira S, Lindsay KL, Levine AM et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004; 101: 4262–4267.
Meijer E, Dekker AW, Weersink AJL, Rozenberg-Arska M, Verdonck LF . Prevention and treatment of Epstein–Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 2002; 119: 596–607.
Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB . Identification of early antigen BZLF/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 1120–1123.
Schmidt W, Anagnostopoulos I, Scherubi H . Virostatic therapy for advanced lymphoproliferation associated with Epstein–Barr virus in an HIV-infected patient. N Engl J Med 2000; 342: 440–441.
Schneider U, Ruhnke M, Delecluse HJ, Stein H, Huhn D . Regression of Epstein–Barr virus associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. Ann Hematol 2000; 79: 214–216.
Pastore RD, Chadburn A, Kripas C, Schattner EJ . Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 2002; 111: 1112–1115.
Hocqueloux L, Agbalika F, Oksenhendler E, Molina J-M . Long term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15: 280–282.
Lee RK, Cai JP, Deyev V, Gill PS, Cabral L, Wood C et al. Azidothymidine and interferon-alpha induce apoptosis in herpesvirus-associatedlymphomas. Cancer Res 1999; 59: 5514–5520.
Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kB. Blood 2003; 101: 2321–2327.
Casper C, Nichols G, Huang M-L, Corey L, Wald A . Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103: 1632–1634.
Kedes DH, Ganem D . Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99: 2082–2086.
Gill PS, Harrington Jr W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA et al. Treatment of adult T-cell leukemia–lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744–1748.
Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N et al. Brief report: treatment of adult T-cell leukemia–lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749–1751.
Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004; 5: 130–134.
Jaffe ES . Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 2004; 96: 571–573.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luppi, M., Barozzi, P., Potenza, L. et al. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?. Leukemia 18, 1572–1575 (2004). https://doi.org/10.1038/sj.leu.2403447
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403447